{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Major+Salivary+Gland+Carcinoma&page=2",
    "query": {
      "condition": "Major Salivary Gland Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Major+Salivary+Gland+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:12:57.967Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01256385",
      "title": "Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Verrucous Carcinoma",
        "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Verrucous Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Salivary Gland Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Stage IVA Laryngeal Squamous Cell Carcinoma",
        "Stage IVA Laryngeal Verrucous Carcinoma",
        "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma",
        "Stage IVA Major Salivary Gland Carcinoma",
        "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVA Oral Cavity Verrucous Carcinoma",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVB Laryngeal Squamous Cell Carcinoma",
        "Stage IVB Laryngeal Verrucous Carcinoma",
        "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma",
        "Stage IVB Major Salivary Gland Carcinoma",
        "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVB Oral Cavity Verrucous Carcinoma",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVC Laryngeal Squamous Cell Carcinoma",
        "Stage IVC Laryngeal Verrucous Carcinoma",
        "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma",
        "Stage IVC Major Salivary Gland Carcinoma",
        "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVC Oral Cavity Verrucous Carcinoma",
        "Stage IVC Oropharyngeal Squamous Cell Carcinoma",
        "Tongue Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2010-11",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01256385"
    },
    {
      "nct_id": "NCT02538510",
      "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharynx Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage III Major Salivary Gland Carcinoma",
        "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage III Nasopharyngeal Carcinoma",
        "Stage IV Nasopharyngeal Carcinoma",
        "Stage IVA Major Salivary Gland Carcinoma",
        "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVB Major Salivary Gland Carcinoma",
        "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVC Major Salivary Gland Carcinoma",
        "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-10-08",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538510"
    },
    {
      "nct_id": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Colon Carcinoma",
        "Advanced Colorectal Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Salivary Gland Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "HER2-Positive Breast Carcinoma",
        "Malignant Hepatobiliary Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Colon Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Salivary Gland Carcinoma",
        "Stage III Colon Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Major Salivary Gland Cancer AJCC v8",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Major Salivary Gland Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Unresectable Breast Carcinoma",
        "Unresectable Colon Carcinoma",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Carcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2021-08-09",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 23,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704661"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 818,
      "start_date": "2017-01-30",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1007,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT00897793",
      "title": "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "venipuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-01",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897793"
    },
    {
      "nct_id": "NCT03749460",
      "title": "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Malignant Neoplasm in the Lung",
        "Salivary Gland Carcinoma",
        "Stage IV Major Salivary Gland Cancer AJCC v8",
        "Stage IVA Major Salivary Gland Cancer AJCC v8",
        "Stage IVB Major Salivary Gland Cancer AJCC v8",
        "Stage IVC Major Salivary Gland Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-01-15",
      "completion_date": "2023-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749460"
    },
    {
      "nct_id": "NCT00002632",
      "title": "Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 32,
      "start_date": "1995-05-30",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 28,
      "location_summary": "Palo Alto, California • Stanford, California • Tampa, Florida + 21 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002632"
    },
    {
      "nct_id": "NCT01254617",
      "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Colon Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Verrucous Carcinoma",
        "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Verrucous Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Salivary Gland Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Colon Cancer AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Verrucous Carcinoma AJCC v7",
        "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Rectal Cancer AJCC v7",
        "Stage IVB Colon Cancer AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Verrucous Carcinoma AJCC v7",
        "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Rectal Cancer AJCC v7",
        "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Laryngeal Verrucous Carcinoma AJCC v7",
        "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVC Major Salivary Gland Cancer AJCC v7",
        "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Tongue Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2011-02-10",
      "completion_date": "2014-01-29",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01254617"
    },
    {
      "nct_id": "NCT00003251",
      "title": "Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Head and Neck Cancer",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "1997-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003251"
    },
    {
      "nct_id": "NCT00126607",
      "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Salivary Gland Mucoepidermoid Carcinoma",
        "Recurrent Salivary Gland Cancer",
        "Salivary Gland Acinic Cell Tumor",
        "Salivary Gland Adenocarcinoma",
        "Salivary Gland Poorly Differentiated Carcinoma",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVC Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-05-22T03:12:57.967Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126607"
    }
  ]
}